Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy.

Salem ML, El-Badawy A.

World J Hepatol. 2015 Oct 18;7(23):2449-58. doi: 10.4254/wjh.v7.i23.2449. Review.


Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins.

Bellanti F, Lauletta G, Villani R, Lipsi MR, Natalicchio MI, Sansonno D, Vendemiale G, Serviddio G.

Medicine (Baltimore). 2015 Sep;94(35):e1409. doi: 10.1097/MD.0000000000001409.


Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b.

Wang M, Zhang Y, Li Z, Zhang H, Zhang Z, Yue D, Zhou R, Li X, Wu S, Li J.

Int J Clin Exp Med. 2015 May 15;8(5):7446-56. eCollection 2015.


The Distribution of Genotype and Allelic Frequency of IL28B Gene Polymorphism in Andhra Pradesh, India.

Sivaprasad S, Rao PN, Gupta R, Ashwini K, Reddy DN.

J Clin Exp Hepatol. 2012 Jun;2(2):112-5. doi: 10.1016/S0973-6883(12)60098-X. Epub 2012 Jul 21.


Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making.

Puri CP.

J Clin Exp Hepatol. 2011 Jun;1(1):27-33. doi: 10.1016/S0973-6883(11)60115-1. Epub 2011 Aug 26.


Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C.

Cortez KJ, Kottilil S.

Ther Adv Chronic Dis. 2015 Jan;6(1):4-14. doi: 10.1177/2040622314551934. Review.


Age cohort differences in illicit drug use and hepatitis C among African American substance users.

Whitehead NE, Hearn L, Trenz RC, Burrell LE 2nd, Latimer WW.

J Addict Dis. 2014;33(4):314-21. doi: 10.1080/10550887.2014.969605.


An interferon response gene signature is associated with the therapeutic response of hepatitis C patients.

Pfeffer LM, Li K, Fleckenstein JF, Marion TN, Diament J, Yang CH, Pfeffer SR, Fan M, Handorf E, Handorf CR.

PLoS One. 2014 Aug 11;9(8):e104202. doi: 10.1371/journal.pone.0104202. eCollection 2014.


Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children.

Indolfi G, Azzari C, Resti M.

World J Gastroenterol. 2014 Jul 28;20(28):9245-52. doi: 10.3748/wjg.v20.i28.9245.


KASL clinical practice guidelines: management of hepatitis C.

Korean Association for the Study of the Liver (KASL).

Clin Mol Hepatol. 2014 Jun;20(2):89-136. doi: 10.3350/cmh.2014.20.2.89. Epub 2014 Jun 30. No abstract available.


Evaluated outcomes in patients with Chronic Hepatitis C.

Ashtari S, Vahedi M, Amin Pourhoseingholi M, Reza Zali M.

Gastroenterol Hepatol Bed Bench. 2013;6(Suppl 1):S58-64.


Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients.

Balagopal A, Kandathil AJ, Higgins YH, Wood J, Richer J, Quinn J, Eldred L, Li Z, Ray SC, Sulkowski MS, Thomas DL.

Hepatology. 2014 Aug;60(2):477-86. doi: 10.1002/hep.27158. Epub 2014 May 14.


Individualization of chronic hepatitis C treatment according to the host characteristics.

Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN.

World J Gastroenterol. 2014 Mar 21;20(11):2839-53. doi: 10.3748/wjg.v20.i11.2839. Review.


Admixture analysis of spontaneous hepatitis C virus clearance in individuals of African descent.

Wojcik GL, Thio CL, Kao WH, Latanich R, Goedert JJ, Mehta SH, Kirk GD, Peters MG, Cox AL, Kim AY, Chung RT, Thomas DL, Duggal P.

Genes Immun. 2014 Apr;15(4):241-6. doi: 10.1038/gene.2014.11. Epub 2014 Mar 13.


Comparative analysis of rs12979860 SNP of the IFNL3 gene in children with hepatitis C and ethnic matched controls using 1000 Genomes Project data.

Indolfi G, Mangone G, Bartolini E, Nebbia G, Calvo PL, Moriondo M, Tovo PA, de Martino M, Azzari C, Resti M.

PLoS One. 2014 Jan 17;9(1):e85899. doi: 10.1371/journal.pone.0085899. eCollection 2014.


Hepatitis C virus NS3 inhibitors: current and future perspectives.

Salam KA, Akimitsu N.

Biomed Res Int. 2013;2013:467869. doi: 10.1155/2013/467869. Epub 2013 Oct 27. Review.


Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFNαR2a.

Lee YJ, Zhang X, Vazquez E, Shivasabesan G, Young HA, Murphy A, Wang H, Suffredini AF, Siebenlist U, Kottilil S.

J Interferon Cytokine Res. 2014 Jan;34(1):28-34. doi: 10.1089/jir.2013.0032. Epub 2013 Oct 30.


Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.

Muir AJ, Gong L, Johnson SG, Lee MT, Williams MS, Klein TE, Caudle KE, Nelson DR; Clinical Pharmacogenetics Implementation Consortium (CPIC).

Clin Pharmacol Ther. 2014 Feb;95(2):141-6. doi: 10.1038/clpt.2013.203. Epub 2013 Oct 4.


Hepatitis B and C in African Americans: current status and continued challenges.

Forde KA, Tanapanpanit O, Reddy KR.

Clin Gastroenterol Hepatol. 2014 May;12(5):738-48. doi: 10.1016/j.cgh.2013.06.006. Epub 2013 Jun 28. Review.


Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment.

Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, Yokosuka O.

Int J Med Sci. 2013 Jun 15;10(8):1015-21. doi: 10.7150/ijms.6402. Print 2013.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk